Last reviewed · How we verify
Cetuximab + FOLFIRI
Cetuximab blocks EGFR signaling while FOLFIRI chemotherapy damages DNA, together targeting colorectal cancer cells through dual mechanisms.
Cetuximab blocks EGFR signaling while FOLFIRI chemotherapy damages DNA, together targeting colorectal cancer cells through dual mechanisms. Used for Metastatic colorectal cancer, KRAS wild-type, Recurrent or metastatic colorectal cancer as first-line or later-line therapy.
At a glance
| Generic name | Cetuximab + FOLFIRI |
|---|---|
| Also known as | FOLFIRI = irinotecan + calcium folinate + 5-fluorouracil |
| Sponsor | Cinnagen |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | EGFR (cetuximab component); Topoisomerase I (irinotecan component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cetuximab is a monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR), blocking downstream proliferation signals in cancer cells. FOLFIRI is a chemotherapy regimen combining fluorouracil, leucovorin, and irinotecan that damages DNA and inhibits topoisomerase I. The combination leverages targeted immunotherapy with cytotoxic chemotherapy to enhance efficacy in EGFR-expressing colorectal cancers.
Approved indications
- Metastatic colorectal cancer, KRAS wild-type
- Recurrent or metastatic colorectal cancer as first-line or later-line therapy
Common side effects
- Acneiform rash
- Diarrhea
- Neutropenia
- Nausea/vomiting
- Fatigue
- Infusion reactions
- Hypomagnesemia
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (PHASE1)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (PHASE1)
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer (EARLY_PHASE1)
- TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetuximab + FOLFIRI CI brief — competitive landscape report
- Cetuximab + FOLFIRI updates RSS · CI watch RSS
- Cinnagen portfolio CI